AMAafeen Mujeeb

Aafeen Mujeeb

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aafeen Mujeeb has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Persistent Immune Thrombocytopenia as a Post‐Acute Sequelae of COVID‐19: A Case Report

    by Riazullah, Hakim Ullah Wazir, Aafeen Mujeeb, Hamid Ahmad, Hameed Ur Rehman, Inibehe Ime Okon

    Immune thrombocytopenia (ITP) is a recognized hematologic complication associated with coronavirus disease 2019 (COVID‐19), but its persistence years after acute infection remains uncommon. We present a case of a 52‐year‐old male who was diagnosed with COVID‐19 in June 2020. Following recovery from the acute illness, he had persistent fatigue, reduced energy levels, and poor appetite. Laboratory testing at his first follow‐up revealed thrombocytopenia with a platelet count of 60,000/mm 3 . He had no bleeding manifestations or organomegaly. A trial of oral corticosteroids in a tapering dose produced a partial response, with the platelet count rising to 94,000/mm 3 . Subsequently, a bone marrow biopsy was performed, confirming the diagnosis of ITP, excluding infiltration and dysplasia. Over the following 5 years, the patient continued to demonstrate persistent thrombocytopenia requiring a close clinical monitoring and follow‐up. This case highlights persistent ITP as a long‐term sequela of COVID‐19, extending more than 4 years after the initial infection. It underscores the importance of considering post‐COVID hematologic complications in patients presenting with chronic thrombocytopenia and emphasizes the need for ongoing surveillance and individualized management strategies.

  • Open Access

    Using Hepatitis B Surface Antigen–Positive Donors in Liver Transplantation: Outcomes, Prophylaxis, and Monitoring with a Focus on Hepatitis B Virus–Naive Recipients

    by Ali Emre Bardak, Aafeen Mujeeb, Ayse Eylul Donmez, Nazli Begum Ozturk, Eda Yildiz, Hemeesh Tandel, Merih Deniz Toruner, Merve Gurakar, Behnam Saberi, Nilay Danis, et al.

    Liver transplantation (LT) remains the only definitive treatment for end-stage liver disease and selected hepatic malignancies. However, persistent organ shortages continue to drive high waitlist mortality worldwide. Hepatitis B virus (HBV)-positive donors, including hepatitis B surface antigen (HBsAg)-positive and anti-hepatitis B core antibody–positive (HBsAg negative) donors, represent an increasingly important but historically underused resource. The introduction of high-barrier nucleos(t)ide analogs, the selective use of hepatitis B immunoglobulin, and pre- and posttransplant vaccination have markedly reduced viral transmission, enabling safe transplantation in both HBV-immune and selected HBV-naive recipients. Regional guidelines and consensus statements, including those from the American Society of Transplantation, European Association for the Study of the Liver, American Association for the Study of Liver Diseases, and Asian Pacific Association for the Study of the Liver, support individualized, risk-directed prophylaxis and posttransplant surveillance. Ethical considerations, particularly informed consent and risk–benefit discussions in the setting of organ scarcity, remain central to clinical decision-making. Large cohort studies demonstrate comparable graft and patient survival with HBV-negative grafts, along with economic advantages and expansion of the donor pool. However, evidence in HBV-naive recipients remains limited, with most data derived from immune or previously infected recipients, highlighting the need for careful patient selection and robust prophylaxis. Available evidence on the use of HBsAg-positive donors in HBV-naive recipients is obtained predominantly from cadaveric donor transplantation, as experience with HBsAg-positive living donors remains limited. This narrative review summarizes current evidence on the use of HBsAg-positive grafts in LT, with a focus on HBV-naive recipients, based predominantly on cadaveric donor experience. Cite this article as: Bardak AE, Mujeeb A, Donmez AE, et al. Using hepatitis B surface antigen–positive donors in liver transplantation: Outcomes, prophylaxis, and monitoring with a focus on hepatitis B virus–naive recipients. Turk J Gastroenterol. Published online May 13, 2026. doi: 10.5152/tjg.2026.26018.